A consortium of European and US-based investors and Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage bio...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK...
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
FDA supports advancement of IVMED-85 into Phase 2 clinical development for pediatric myopia and provides alignment on key elements of the develop...
ArisGlobal brings a mission-critical, AI-native platform spanning regulatory, safety, quality and medical affairs that serves as a single sourc...
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of ...
Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal&rsquo...
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type ...
Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, annou...
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, announced the expansion of its mu...
Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced a collaborative system-level framework for inject...
-Crown Bioscience is a global contract research organization (CRO) specializing in oncology drug discovery and development, today announced it has joined...
GEM Global Yield LLC SCS ("GEM") has executed a Share Purchase Agreement (the "SPA") with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc...
ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibit...
© 2026 Biopharma Boardroom. All Rights Reserved.
